Skip to main content
Fig. 3 | Acta Neuropathologica Communications

Fig. 3

From: Restoration of histone acetylation ameliorates disease and metabolic abnormalities in a FUS mouse model

Fig. 3

ACY-738 therapy ameliorates ALS disease phenotype in Tg FUS+/+ mice. a Kaplan-Meier survival analysis of vehicle- and ACY-738-treated (100 mg/kg ACY-738 in chow) Tg FUS+/+ mice. Median life span of vehicle-treated Tg FUS+/+ mice is 59 days, that of ACY-738-treated Tg FUS+/+ mice is 99 days. n = 23-25, of which 12 males and 11 females in the vehicle-treated group and 10 males and 15 females in the ACY-738-treated group, Log-rank test. b Disease duration of vehicle- and ACY-738-treated Tg FUS+/+ mice. n = 12–14, Two-tailed t-test. c Longitudinal follow-up of weight, d forelimb grip strength, e hanging wire performance, and f compound muscle action potential (CMAP) amplitudes of vehicle- and ACY-738-treated Tg FUS+/+ mice. n = 10–14, mice were followed up twice a week, Student’s t-test with Holm-Sidak method to correct for multiple testing. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Data are presented as means ± SEM

Back to article page